CEL vs. CNSL, FOX, OTT, BCE, CZN, CHT, DVW, BRCI, NPT, and RCI
Should you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Fox Marble (FOX), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry.
Celadon Pharmaceuticals vs.
Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.
Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals.
Celadon Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, meaning that its share price is 289% more volatile than the S&P 500.
Celadon Pharmaceuticals has a net margin of 0.00% compared to Cambridge Nutritional Sciences' net margin of -3.36%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.
In the previous week, Celadon Pharmaceuticals had 1 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 2 mentions for Celadon Pharmaceuticals and 1 mentions for Cambridge Nutritional Sciences. Cambridge Nutritional Sciences' average media sentiment score of 0.54 beat Celadon Pharmaceuticals' score of 0.02 indicating that Cambridge Nutritional Sciences is being referred to more favorably in the news media.
10.7% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Celadon Pharmaceuticals received 4 more outperform votes than Cambridge Nutritional Sciences when rated by MarketBeat users.
Summary
Celadon Pharmaceuticals beats Cambridge Nutritional Sciences on 7 of the 13 factors compared between the two stocks.
Get Celadon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celadon Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:CEL) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CEL Stock Alerts